Lumykras : EPAR - Risk management plan

Human medicines European public assessment report (EPAR): Orkambi, lumacaftor,ivacaftor, Date of authorisation: 19/11/2015, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Ryjunea, atropine sulfate, Date of authorisation: 02/06/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Voriconazole Accord, voriconazole, Date of authorisation: 16/05/2013, Revision: 23, Status: Authorised

Academia

Human medicines European public assessment report (EPAR): Plerixafor Accord, plerixafor, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Braftovi, encorafenib, Date of authorisation: 19/09/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Zeffix, lamivudine, Date of authorisation: 29/07/1999, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Zonegran, zonisamide, Date of authorisation: 10/03/2005, Revision: 38, Status: Authorised